Selsym Biotech, Inc.
SelSym Biotech is dedicated to developing innovative therapeutics to address critical clinical needs in hemorrhage control, surgical bleeding, and wound healing. Their mission is to transform patient care and outcomes through advanced technologies like their Hemostatic Healing Hydrogels and SymClot, a novel therapy that mimics platelet functions to enhance hemorrhage control and address platelet supply shortages.
Industries
Nr. of Employees
small (1-50)
Products
Intravenous fibrin-targeted synthetic platelet therapy
An injectable synthetic platelet-mimetic hydrogel particle designed to home to fibrin at bleeding sites, bind fibrin networks, and mechanically induce clot retraction to reduce bleeding and support wound healing.
Hemostatic Healing Hydrogel (H3) platform
A tunable hydrogel platform engineered for a range of clinical needs in bleeding management and wound healing, including hemorrhage control, controlled drug delivery, infection control, and long-term support of chronic wounds.
Intravenous fibrin-targeted synthetic platelet therapy
An injectable synthetic platelet-mimetic hydrogel particle designed to home to fibrin at bleeding sites, bind fibrin networks, and mechanically induce clot retraction to reduce bleeding and support wound healing.
Hemostatic Healing Hydrogel (H3) platform
A tunable hydrogel platform engineered for a range of clinical needs in bleeding management and wound healing, including hemorrhage control, controlled drug delivery, infection control, and long-term support of chronic wounds.
Expertise Areas
- Hemorrhage control therapeutics
- Biomimetic hemostatic materials
- Synthetic platelet and microgel particle design
- Wound healing biomaterials and drug delivery
Key Technologies
- Hemostatic hydrogels (tunable H3 platform)
- Deformable hydrogel microgels
- Fibrin-targeting antibody fragments / fibrin-binding ligands
- Lyophilization (freeze-drying) and reconstitution